Inspire Medical Systems (NYSE:INSP) Upgraded at Oppenheimer

Oppenheimer upgraded shares of Inspire Medical Systems (NYSE:INSP) from a market perform rating to an outperform rating in a research note issued to investors on Tuesday, MarketBeat reports. Oppenheimer currently has $85.00 target price on the stock.

A number of other equities analysts have also weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. Freedom Capital upgraded shares of Inspire Medical Systems to a “strong-buy” rating in a report on Tuesday, June 30th. Weiss Ratings cut shares of Inspire Medical Systems from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, May 6th. Mizuho dropped their price objective on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Finally, Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $68.00.

Inspire Medical Systems Trading Down 2.0%

NYSE INSP opened at $58.91 on Tuesday. Inspire Medical Systems has a 12 month low of $38.91 and a 12 month high of $147.03. The stock has a market cap of $1.70 billion, a PE ratio of 12.75, a P/E/G ratio of 4.55 and a beta of 0.70. The stock’s 50 day moving average is $47.26 and its 200 day moving average is $54.48.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s revenue was down 7.6% on a year-over-year basis. During the same period last year, the firm posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Inspire Medical Systems

Several large investors have recently bought and sold shares of the business. CWM LLC raised its stake in Inspire Medical Systems by 216.1% during the fourth quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after purchasing an additional 242 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Inspire Medical Systems by 1,115.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after buying an additional 580 shares in the last quarter. Havemeyer Place LP purchased a new position in shares of Inspire Medical Systems in the 4th quarter worth $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems in the 4th quarter worth about $40,000. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Inspire Medical Systems by 84.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after buying an additional 205 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.